Last reviewed · How we verify

Continuos ceftazidime/avibactam infusion

Ivan Šitum, MD · FDA-approved active Small molecule

Continuos ceftazidime/avibactam infusion is a Beta-lactam/beta-lactamase inhibitor combination Small molecule drug developed by Ivan Šitum, MD. It is currently FDA-approved for Complicated urinary tract infections (cUTI) including pyelonephritis, Complicated intra-abdominal infections (cIAI), Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

Ceftazidime/avibactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.

Ceftazidime/avibactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation. Used for Complicated urinary tract infections (cUTI) including pyelonephritis, Complicated intra-abdominal infections (cIAI), Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

At a glance

Generic nameContinuos ceftazidime/avibactam infusion
SponsorIvan Šitum, MD
Drug classBeta-lactam/beta-lactamase inhibitor combination
TargetPenicillin-binding proteins (PBPs); serine beta-lactamases
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Ceftazidime is a third-generation cephalosporin that binds to penicillin-binding proteins and disrupts bacterial cell wall synthesis. Avibactam is a non-beta-lactam beta-lactamase inhibitor that protects ceftazidime from degradation by serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), AmpC beta-lactamases, and some carbapenemases. Continuous infusion delivery maintains sustained bactericidal concentrations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Continuos ceftazidime/avibactam infusion

What is Continuos ceftazidime/avibactam infusion?

Continuos ceftazidime/avibactam infusion is a Beta-lactam/beta-lactamase inhibitor combination drug developed by Ivan Šitum, MD, indicated for Complicated urinary tract infections (cUTI) including pyelonephritis, Complicated intra-abdominal infections (cIAI), Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

How does Continuos ceftazidime/avibactam infusion work?

Ceftazidime/avibactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.

What is Continuos ceftazidime/avibactam infusion used for?

Continuos ceftazidime/avibactam infusion is indicated for Complicated urinary tract infections (cUTI) including pyelonephritis, Complicated intra-abdominal infections (cIAI), Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), Carbapenem-resistant Enterobacteriaceae (CRE) infections.

Who makes Continuos ceftazidime/avibactam infusion?

Continuos ceftazidime/avibactam infusion is developed and marketed by Ivan Šitum, MD (see full Ivan Šitum, MD pipeline at /company/ivan-itum-md).

What drug class is Continuos ceftazidime/avibactam infusion in?

Continuos ceftazidime/avibactam infusion belongs to the Beta-lactam/beta-lactamase inhibitor combination class. See all Beta-lactam/beta-lactamase inhibitor combination drugs at /class/beta-lactam-beta-lactamase-inhibitor-combination.

What development phase is Continuos ceftazidime/avibactam infusion in?

Continuos ceftazidime/avibactam infusion is FDA-approved (marketed).

What are the side effects of Continuos ceftazidime/avibactam infusion?

Common side effects of Continuos ceftazidime/avibactam infusion include Diarrhea, Nausea, Headache, Phlebitis at infusion site, Hypersensitivity reactions.

What does Continuos ceftazidime/avibactam infusion target?

Continuos ceftazidime/avibactam infusion targets Penicillin-binding proteins (PBPs); serine beta-lactamases and is a Beta-lactam/beta-lactamase inhibitor combination.

Related